AbbVie Header AbbVie Header

X

Find the latest Drugs in Development and Pipeline Prospector News of IDT Biologika GmbH.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
IDT Biologika GmbH
Germany Flag
Country
Country
Germany
Address
Address
Am Pharmapark, 06861 Dessau-Rosslau
Telephone
Telephone
+49 34901 885-0

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

left grey arrow
right gray arrow

Details:

VLA2001 is produced on Valneva’s established Vero-cell platform, leveraging technology. VLA2001 consists of inactivated whole virus particles of SARS-CoV-2 with high S-protein density, in combination with two adjuvants, alum and CpG 1018.


Lead Product(s): VLA2001,CpG 1018,Aluminium Hydroxide

Therapeutic Area: Infections and Infectious Diseases Product Name: VLA2001

Highest Development Status: ApprovedProduct Type: Vaccine

Partner/Sponsor/Collaborator: Valneva

Deal Size: $39.9 million Upfront Cash: $35.5 million

Deal Type: Termination September 16, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

A coronavirus vaccine, MVA-SARS-2-S vaccine, developed by the German Centre for Infection Research (DZIF) and vaccine maker IDT Biologika did not prompt the hoped-for immune reaction in early-stage testing on humans.


Lead Product(s): MVA-SARS-2-S vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: MVA-SARS-2-S vaccine

Highest Development Status: Phase IProduct Type: Vaccine

Recipient: German Center for Infection Research

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 08, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The trial of the vaccine, which has been developed with the German Centre for Infection Research (DZIF), will be conducted on 30 participants aged between 18 and 55 who will receive two vaccinations at four-week intervals.


Lead Product(s): MVA-SARS-2-S vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: MVA-SARS-2-S vaccine

Highest Development Status: Phase IProduct Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 02, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY